If you liked this article you might like

Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps
Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait
Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market
Mylan Has Been Pounded, but the Pain May be Far from Over